Sepsis, a life-threatening condition marked by an overwhelming immune response to infection, presents a formidable challenge to clinicians worldwide. The relentless cascade of inflammatory mediators, including cytokines like interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α), coupled with circulating endotoxins and damage-associated molecular patterns, creates a vicious cycle of systemic inflammation. This process precipitates vasoplegia, capillary leak syndrome, microcirculatory failure, and ultimately multi-organ dysfunction. Conventional pharmacological interventions often fall short, leaving critical care providers searching for advanced therapeutic options to stabilize the most vulnerable patients. Enter the oXiris® membrane—a novel dual-function extracorporeal device designed to simultaneously support renal function and modulate the hyperinflammatory milieu of sepsis.
The oXiris® membrane builds upon a foundation of modified acrylonitrile and sodium methallyl sulfonate (AN69) hydrogel, a polymer known for its biocompatibility and dialysis efficacy. This base is complemented by a polyethyleneimine (PEI) coating that imparts a positive surface charge, augmenting the membrane’s capacity to adsorb negatively charged endotoxins. Additionally, a heparin-grafted surface promotes hemocompatibility, reducing thrombogenesis and clotting risks during prolonged extracorporeal circulation. This sophisticated three-layer structure integrates diffusion, convection, and adsorption, effectively combining renal replacement therapy with immunomodulatory blood purification. The design addresses multiple pathophysiological facets of sepsis, providing a versatile platform that transcends standard dialysis membranes.
Clinical experience with oXiris® in septic shock and sepsis-associated acute kidney injury is growing, marked by encouraging though preliminary data. Observational studies and small randomized controlled trials have consistently reported early physiological improvements following treatment initiation. These include reduced vasopressor dependency, improved hemodynamic stability, and significant decreases in circulating proinflammatory cytokines and endotoxin activity. Enhanced lactate clearance and early amelioration of organ dysfunction scores further underscore the membrane’s potential to interrupt the downward spiral characteristic of severe sepsis. Such findings suggest that oXiris® is more than a renal support tool — it is a modulatory device that directly combats the destructive inflammatory milieu.
Meta-analyses encompassing these investigations hint at a possible short-term mortality benefit, although the evidence remains limited by study heterogeneity, small sample populations, and absence of large-scale randomized trials. Despite these caveats, experts emphasize that the oXiris® membrane should not be viewed as a monotherapy. Instead, it must be integrated within comprehensive sepsis management encompassing timely administration of antibiotics, rigorous source control, and nuanced supportive care. The greatest therapeutic successes appear contingent on early identification and intervention within the dynamic course of septic shock and kidney injury.
Beyond sepsis, the oXiris® membrane is charting pathways into other critical care domains characterized by complex inflammatory pathology. In cardiac surgery, extracorporeal blood purification with oXiris® during cardiopulmonary bypass has demonstrated a significant reduction in incidence and severity of postoperative acute kidney injury in high-risk cohorts. This application reflects the membrane’s adaptability and potential to mitigate ischemia-reperfusion injury and systemic inflammatory response syndrome induced by major surgery. Such findings herald new opportunities for perioperative organ protection using tailor-made extracorporeal therapies.
In the arena of viral infections, particularly severe COVID-19, the oXiris® membrane’s immunomodulatory properties have been explored in several observational cohorts. Rapid reductions in IL-6 levels have been documented alongside improved hemodynamics and oxygenation parameters. Although physiological improvements have been compelling, the translation into enhanced survival rates remains inconsistent. This discrepancy highlights the multifactorial nature of viral sepsis syndromes and underscores the need for precise patient selection and timing when considering extracorporeal immunomodulation.
Cardiogenic shock and use of extracorporeal membrane oxygenation (ECMO) represent an additional frontier where oXiris® has been tested. However, findings from randomized controlled trials thus far have been neutral or mixed, likely reflecting the heterogeneous pathophysiology and inflammatory phenotypes in these critically ill populations. These experiences reinforce that the success of extracorporeal blood purification hinges on appropriate clinical context and phenotype-driven therapy rather than broad application.
A critical lesson emerging from the literature is the paramount importance of selecting the right patient at the right stage of illness. Ideal candidates for oXiris® therapy often display elevated inflammatory burden combined with endotoxemia, early refractory vasoplegic shock, and sepsis-associated acute kidney injury requiring continuous renal replacement therapy (CRRT). Expert consensus recommends initiating treatment within 6 to 12 hours after shock onset to maximize immunomodulatory impact. Ongoing clinical reassessment within 24 to 48 hours—monitoring vasopressor requirements, lactate levels, and inflammatory biomarkers—should guide decisions to continue or discontinue therapy, ensuring personalized and dynamic treatment strategies.
Nonetheless, important limitations and knowledge gaps remain. The non-selective nature of adsorption risks unintended removal of antibiotics or beneficial immune mediators, necessitating vigilant therapeutic drug monitoring. Implementation challenges such as high costs, technical demands, and variability in operator experience across centers further constrain widespread adoption. Most crucially, the absence of large-scale, rigorously designed randomized controlled trials perpetuates uncertainty concerning long-term benefits, cost-effectiveness, and optimal protocols.
Looking forward, the future of extracorporeal immunomodulation lies in precision medicine approaches that tailor intervention to individual patient inflammatory phenotypes. Sequential or combined therapies—potentially integrating different adsorption technologies, filtration modalities, or immune plasma exchange—may enable finer targeting of dominant inflammatory drivers at different disease stages. The oXiris® membrane embodies a pivotal advance in this evolutionary path, merging renal support and immunomodulation into a single platform while laying groundwork for refined, personalized extracorporeal treatments.
In sum, while not a panacea for the intricate pathology of sepsis, the oXiris® membrane represents a significant innovation in critical care technology. By offering a dual-function device that combines effective renal replacement with immunomodulatory blood purification, it provides intensivists a vital tool to stabilize and buy time for the sickest patients. The membrane’s ultimate clinical value will depend on prudent patient selection, early initiation, ongoing reassessment, and integration within comprehensive sepsis protocols. As research advances and more robust evidence emerges, oXiris® stands poised to redefine the landscape of extracorporeal therapies in the intensive care unit.
Subject of Research: Not applicable
Article Title: Clinical applications of oXiris membranes: Targeting inflammation and renal dysfunction in ICU patients
News Publication Date: 27-Feb-2026
References: DOI: 10.1016/j.jointm.2025.11.005
Image Credits: Silvia De Rosa, University of Trento, Italy
